Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution

Ducord, HPC (Hematopoietic Progenitor Cell) Cord Blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated-donor hematopoietic progenitor stem cell transplantation procedures. The therapy is delivered in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. Matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended. Recovery of critical T cell subsets of recipients is delayed but reaches levels comparable to recipients of matched sibling donor (MSD)/matched unrelated donor (MUD) cells by 12 months after transplantation. In addition, the T cell repertoire is comparably diversified in the UCB and MSD/MUD recipients at 12 months after transplantation. NK and B cell recovery is more rapid in UCB recipients. The progression-free survival between recipients of UCB and MSD/MUD HCT is comparable.